NPS+ Psoriasis (US) - New Report Available

Psoriasis: Low loyalty levels & high competition, how does your brand stack up?

Physicians in the psoriasis market are showing decidedly low levels of loyalty, but high levels of satisfaction among the available brands. Find out what brand messages are being associated with your brand, what effect they have on physicians' recommendations, and, critically, how your brand compares to your competitors.

FirstView's NPS+ Psoriasis report compares brand loyalty for 6 major psoriasis treatments-information you can use to improve your brand's health, and boost your market share.

Based on your net promoter score (NPS), the report shows you how likely doctors are to recommend your brand-and your competitors. A detailed breakdown of brand associations helps you see which marketing messages are likely to succeed, while a unique "Brand DNA" section reveals doctors' candid thoughts about your brand.

Full Report Details at
- http://www.fastmr.com/prod/1180413_nps+_psoriasis_us.aspx?afid=301

Intuitive, easy-to-use KPIs highlight areas for improvement and make your next steps crystal clear.

Reasons to Get this Report

Get Answers to Key Questions about Psoriasis Treatments

* Stelara (ustekinumab; Janssen Biotech): Are physicians considering another brand as interchangeable with Stelara?
* Humira (adalimumab; AbbVie): Neck & neck with a key competitor, does the route of administration involved in prescribing Humira stop physicians from recommending it?
* Enbrel (etanercept; Amgen): Several promoters state that this is a safe & reliable brand, but what factors are creating a number of concerns?
* Cosentyx (secukinumab; Novartis): Cosentyx & Enbrel have a similar NPS, but which brand would gain more by converting their 'passive prescribers' to 'promoters'?
* Otezla (apremilast; Celgene): Otezla is being described as having a novel MOA, but what effect is this actually having on its NPS?
* Remicade (infliximab; Janssen Biotech): Do the number of passive physicians represent an opportunity for Remicade to increase its NPS?

Top Takeaways

* Top two brands lead with significantly higher NPS: However, the percentage of promoters across all the treatments would suggest a different outcome.
* Physicians true opinions revealed: See verbatim copies of what messages physicians associate with your brand, both positive and negative
* Increased loyalty could improve commercial results: Brands show low to very low levels of loyalty, examining why this is could lead to a significant commercial advantage.
* Several brands have significant opportunities for NPS growth: Several brands will dramatically increase their score by turning their detractive & passive physicians into promoters.
* Drug delivery method key to success or failure for many: The scores for three drugs are dramatically affected, either positively or negatively, by their mechanism of action.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- NPS+ Psoriasis (EU5)
- EpiCast Report: Psoriasis - Epidemiology Forecast to 2024
- NPS Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report
- NPS+ HIV (EU5)
- NPS+ HIV (US)